Health
Excel
Geriatric Diseases Dataset – Age-Related Conditions & Disorders
Geriatric Diseases Dataset
The Geriatric Diseases Dataset is a structured medical database containing a comprehensive list of health conditions commonly affecting older adults and the aging population.
As people age, they become more susceptible to chronic diseases, degenerative conditions, and age-related health issues. This dataset provides organised information about these conditions to support geriatric research, healthcare analytics, and application development.
Each record includes detailed clinical information such as disease descriptions, affected body systems, common symptoms, severity levels, and treatment approaches.
The dataset has been cleaned and structured for easy integration into spreadsheets, databases, and analytical tools.
It is ideal for geriatric medicine researchers, healthcare developers, public health professionals, and data scientists working with aging and longevity-related health data.
Dataset Contents
The dataset includes fields such as:
- Disease / Condition Name
- Description
- Affected System
- Common Symptoms
- Severity Level
- Disease Category
- Age Group (Older Adults / Elderly)
- Treatment / Management
Example Conditions Included
- Alzheimer’s Disease
- Parkinson’s Disease
- Osteoporosis
- Arthritis
- Cardiovascular Disease
- Chronic Kidney Disease
- Dementia
- Age-Related Macular Degeneration
- Hypertension
- Type 2 Diabetes
...and many more age-related conditions.
Data Preview
17 columns
25 rows shown
| ID | Disease Name | Category | Prevalence | Inheritance Pattern | Affected Gene(s) | Chromosome Location | Key Symptoms | Typical Age of Onset | Diagnosis Methods | Available Treatments | Orphan Drug Designation | ICD-10 Code | OMIM Number | Affected System(s) | Disease Severity | Life Expectancy Impact | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | Frailty Syndrome | Geriatric Syndromes | Approximately 10-15% of community-dwelling adults >65 years; rises to >25% in adults >85 (Fried phenotype; Lancet 2019) | Acquired / Multifactorial | N/A | N/A | Unintentional weight loss, exhaustion, weakness (low grip strength), slow gait speed, low physical activity | 65+ years | Fried phenotype criteria, Clinical Frailty Scale, FRAIL scale, comprehensive geriatric assessment | Resistance/aerobic exercise, protein-rich nutrition, vitamin D, medication review, multidisciplinary CGA | No | R54 | N/A | Multisystem | Variable | Moderate reduction |
| 2 | 2 | Sarcopenia | Geriatric Syndromes | Approximately 10-11% in community-dwelling adults >60 years (EWGSOP2); up to 27% in adults >=85 (J Clin Med 2024) | Acquired / Multifactorial | N/A | N/A | Progressive loss of muscle mass and strength, low grip strength, slow gait speed, poor physical performance | 65+ years | EWGSOP2 criteria: SARC-F screen, grip strength, DXA/BIA for muscle mass, gait speed/SPPB | Progressive resistance training, protein supplementation (1.0-1.2 g/kg/day), vitamin D, treat underlying conditions | No | M62.84 | N/A | Musculoskeletal | Variable | Mild reduction |
| 3 | 3 | Recurrent Falls in Older Adults | Geriatric Syndromes | 1 in 4 adults aged >=65 falls annually (CDC 2024); fall death rate 78.4 per 100,000 older adults | Acquired / Multifactorial | N/A | N/A | Two or more falls in 12 months, injury, fear of falling, gait and balance impairment | 65+ years | CDC STEADI algorithm, Timed Up and Go, 30-second chair stand, 4-stage balance test, medication review | Exercise (tai chi, Otago), vitamin D if deficient, home hazard modification, deprescribing, vision correction | No | R29.6 | N/A | Musculoskeletal | Variable | Moderate reduction |
| 4 | 4 | Delirium | Geriatric Syndromes | Approximately 23% pooled prevalence in hospitalized older adults; up to 50% in ICU/post-surgical (Int J Nurs Stud 2024) | Acquired / Multifactorial | N/A | N/A | Acute onset, fluctuating course, inattention, disorganized thinking, altered level of consciousness | 65+ years | CAM (Confusion Assessment Method), 3D-CAM, CAM-ICU, DSM-5-TR criteria, identify precipitants | Treat underlying cause, non-pharmacologic (HELP protocol), reorientation, minimize sedatives, low-dose antipsychotics if severe | No | F05 | N/A | Neurologic | Severe | Moderate reduction |
| 5 | 5 | Pressure Injury, Unspecified Site and Stage | Geriatric Syndromes | Approximately 11% of US nursing home residents (CDC NCHS); 2.5 million US cases annually | Acquired / Multifactorial | N/A | N/A | Localized skin/tissue damage over bony prominence, erythema, ulceration, exposure of muscle/bone in severe stages | 65+ years | NPUAP/EPUAP staging (I-IV, unstageable, deep tissue), Braden Scale risk assessment, clinical exam | Pressure redistribution, repositioning q2h, support surfaces, wound care, nutrition optimization, debridement (WHS 2023) | No | L89.90 | N/A | Integumentary | Variable | Mild reduction |
| 6 | 6 | Polypharmacy | Geriatric Syndromes | Approximately 40% of US adults >=65 take >=5 medications (AGS 2023); PIM prevalence 11-62% | Acquired / Multifactorial | N/A | N/A | Concurrent use of >=5 medications, adverse drug events, drug-drug interactions, cognitive/functional decline | 65+ years | Medication reconciliation, AGS Beers Criteria 2023, STOPP/START criteria, clinical review | Deprescribing, medication reconciliation, avoid Beers-listed PIMs, pharmacist-led review, simplify regimens | No | Z79.899 | N/A | Multisystem | Variable | Mild reduction |
| 7 | 7 | Protein-Energy Malnutrition | Geriatric Syndromes | Approximately 28% high risk in hospitalized, 17.5% residential care, 8.5% community (Eur J Clin Nutr meta-analysis) | Acquired / Multifactorial | N/A | N/A | Weight loss, muscle wasting, reduced albumin, fatigue, impaired wound healing, immunosuppression | 65+ years | Mini Nutritional Assessment (MNA/MNA-SF), GLIM criteria, serum albumin/prealbumin, anthropometry | Oral nutritional supplements, protein-dense meals, treat underlying causes, dietitian referral, enteral feeding if severe | No | E44.0 | N/A | Multisystem | Moderate | Moderate reduction |
| 8 | 8 | Unintentional Weight Loss | Geriatric Syndromes | Affects 13% of elderly outpatients; 27% of frail older adults; up to 50-65% of nursing home residents (AAFP 2021) | Acquired / Multifactorial | N/A | N/A | Loss of >5% body weight over 6-12 months without intent, reduced appetite, fatigue | 65+ years | Weight history, review medications, depression screen, cancer workup, thyroid/metabolic panel, MNA | Identify and treat underlying cause, nutritional support, appetite stimulants if appropriate, manage depression | No | R63.4 | N/A | Multisystem | Variable | Moderate reduction |
| 9 | 9 | Adult Failure to Thrive | Geriatric Syndromes | Approximately 5-25% of community-dwelling elderly; 1.5% of hospitalized older adults coded (AAFP; STAT 2022) | Acquired / Multifactorial | N/A | N/A | Multifactorial decline: weight loss, decreased appetite, poor nutrition, inactivity, depression, cognitive decline | 65+ years | Comprehensive geriatric assessment targeting four syndromes: impaired function, malnutrition, depression, cognitive impairment | Multidisciplinary approach: nutrition, physical/occupational therapy, treat depression, palliative care when appropriate | No | R62.7 | N/A | Multisystem | Severe | Moderate reduction |
| 10 | 10 | Disuse Atrophy / Deconditioning | Geriatric Syndromes | Common in hospitalized older adults; ~30-60% experience functional decline during admission (JAMA) | Acquired / Multifactorial | N/A | N/A | Muscle atrophy and weakness from prolonged immobility, reduced endurance, fatigue, loss of independence in ADLs | 65+ years | Clinical exam, functional assessment (SPPB, gait speed), grip strength, imaging if indicated | Early mobilization, progressive resistance/aerobic exercise, physical therapy, nutritional support | No | M62.3 | N/A | Musculoskeletal | Variable | Mild reduction |
| 11 | 11 | Dysphagia, Unspecified | Geriatric Syndromes | 15-22% in community-dwelling older adults; 40-60% in nursing home residents (Dysphagia 2022 meta-analysis) | Acquired / Multifactorial | N/A | N/A | Difficulty swallowing solids/liquids, coughing/choking with meals, aspiration, weight loss, recurrent pneumonia | 65+ years | Clinical swallow evaluation, videofluoroscopic swallow study (VFSS), FEES, bedside water swallow test | Swallowing therapy, diet texture modification (IDDSI), postural strategies, treat underlying cause, feeding tube if severe | No | R13.10 | N/A | Gastrointestinal | Variable | Moderate reduction |
| 12 | 12 | Chronic Pain Syndrome | Geriatric Syndromes | Approximately 50% of community-dwelling older adults have chronic pain; up to 80% in long-term care (AGS) | Acquired / Multifactorial | N/A | N/A | Persistent pain >3 months with psychosocial dysfunction, sleep disturbance, functional impairment, depression | 65+ years | Pain history, numeric rating scale, PAINAD for dementia, functional assessment, imaging as indicated | Multimodal: acetaminophen, topical NSAIDs, physical therapy, CBT, cautious opioids (avoid per Beers), non-pharmacologic | No | G89.29 | N/A | Multisystem | Variable | Mild reduction |
| 13 | 13 | Alzheimer's Disease, Late Onset | Dementia & Cognitive Disorders | 6.9 million Americans >=65 with AD (2024 Alzheimer's Facts & Figures); 5% of 65-74, 13.2% of 75-84, 33.4% of >=85 | Acquired / Multifactorial | APOE epsilon-4 (risk factor) | 19q13.32 | Progressive memory loss, disorientation, executive dysfunction, language impairment, behavioral changes | 65+ years | NIA-AA criteria, cognitive testing (MMSE/MoCA), MRI, CSF Abeta42/tau, amyloid PET, plasma p-tau217 | Cholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine, anti-amyloid mAbs (lecanemab, donanemab) | No | G30.1 | 104300 | Neurologic | Severe | Reduced without treatment |
| 14 | 14 | Vascular Dementia | Dementia & Cognitive Disorders | 1.4-4.2% prevalence in adults >65; accounts for 15-20% of all dementia cases (AHA 2025 Scientific Statement) | Acquired / Multifactorial | N/A | N/A | Stepwise cognitive decline, executive dysfunction, gait disturbance, focal neurologic signs, mood changes | 65+ years | VASCOG/DSM-5-TR criteria, cognitive testing, brain MRI (infarcts, white matter disease), vascular risk assessment | Vascular risk factor control (BP, lipids, diabetes), antiplatelet therapy, cholinesterase inhibitors may help, rehabilitation | No | F01.50 | N/A | Neurologic | Severe | Reduced without treatment |
| 15 | 15 | Dementia with Lewy Bodies | Dementia & Cognitive Disorders | Approximately 5% of all dementia cases; 0.4% of adults >65 (McKeith 2017; LBDA) | Acquired / Multifactorial | N/A | N/A | Fluctuating cognition, recurrent visual hallucinations, REM sleep behavior disorder, parkinsonism, neuroleptic sensitivity | 65+ years | McKeith 2017 consensus criteria, DaTscan (reduced striatal dopamine), MIBG cardiac scintigraphy, polysomnography | Cholinesterase inhibitors (rivastigmine, donepezil), levodopa for parkinsonism (cautious), avoid typical antipsychotics | No | G31.83 | 127750 | Neurologic | Severe | Reduced without treatment |
| 16 | 16 | Frontotemporal Dementia | Dementia & Cognitive Disorders | Point prevalence 15-22/100,000; most common dementia onset <65 years, but cases extend into older age | Acquired / Multifactorial | MAPT, GRN, C9orf72 (familial forms) | 17q21.31 | Behavioral changes, disinhibition, apathy, language impairment, executive dysfunction, relatively spared memory early | 65+ years | Rascovsky/Lund-Manchester criteria, neuropsychological testing, MRI (frontotemporal atrophy), FDG-PET | Supportive care, SSRIs for behavioral symptoms, speech therapy, caregiver support; no disease-modifying therapy | No | G31.09 | 600274 | Neurologic | Severe | Reduced without treatment |
| 17 | 17 | Mild Cognitive Impairment | Dementia & Cognitive Disorders | 10.1% at ages 70-74, 14.8% at 75-79, 25.2% at 80-84 (global meta-analysis; prevalence 23.7% in geriatric population) | Acquired / Multifactorial | N/A | N/A | Subjective and objective cognitive decline beyond normal aging with preserved functional independence in ADLs | 65+ years | NIA-AA criteria, MoCA/MMSE, neuropsychological testing, MRI, CSF or plasma AD biomarkers when indicated | Aerobic exercise, cognitive training, vascular risk modification, monitor for conversion to dementia, address reversible causes | No | G31.84 | N/A | Neurologic | Mild | Minimal |
| 18 | 18 | Primary Progressive Aphasia | Dementia & Cognitive Disorders | Rare variant of FTLD; estimated 3-4 per 100,000 (Gorno-Tempini 2011 criteria) | Acquired / Multifactorial | GRN, MAPT (some familial cases) | 17q21.31 | Progressive isolated language impairment: nonfluent/agrammatic, semantic, or logopenic variant | 65+ years | Gorno-Tempini 2011 consensus criteria, neuropsychological language testing, MRI (regional atrophy), FDG-PET | Speech-language therapy, augmentative communication, treat underlying AD if logopenic variant, supportive care | No | G31.01 | 172700 | Neurologic | Severe | Reduced without treatment |
| 19 | 19 | Cerebral Amyloid Angiopathy | Dementia & Cognitive Disorders | Moderate-severe CAA in ~30% of brains >=70 years; >50% in those >=90 years at autopsy | Acquired / Multifactorial | APP (familial Dutch-type rare) | 21q21.3 | Lobar intracerebral hemorrhage, transient focal neurologic episodes, cognitive impairment, cortical superficial siderosis | 65+ years | Boston Criteria v2.0, MRI with SWI/GRE (lobar microbleeds, siderosis), pathology is gold standard | Blood pressure control, avoid anticoagulants when possible, manage hemorrhagic risk, supportive care | No | I68.0 | 605714 | Neurologic | Severe | Moderate reduction |
| 20 | 20 | Mixed Dementia (Alzheimer's and Vascular) | Dementia & Cognitive Disorders | Present in up to 50% of dementia cases at autopsy; most common dementia subtype in oldest-old | Acquired / Multifactorial | APOE epsilon-4 (risk factor) | 19q13.32 | Mixed features of AD (memory loss) and vascular dementia (executive dysfunction, stepwise decline) | 75+ years | Clinical criteria combining NIA-AA and VASCOG, MRI showing both atrophy and vascular lesions, biomarkers | Cholinesterase inhibitors, memantine, aggressive vascular risk factor control, rehabilitation, caregiver support | No | G30.9 | N/A | Neurologic | Severe | Reduced without treatment |
| 21 | 21 | Idiopathic Normal Pressure Hydrocephalus | Dementia & Cognitive Disorders | 0.2% at ages 70-79; up to 5.9% at age >=80 (StatPearls; population studies) | Acquired / Multifactorial | N/A | N/A | Hakim triad: gait apraxia (magnetic gait), cognitive impairment, urinary incontinence; enlarged ventricles | 65+ years | Clinical triad, brain MRI/CT (ventriculomegaly without atrophy), high-volume LP tap test, lumbar drain trial | Ventriculoperitoneal shunt (60-80% improvement, gait responds best); programmable valves | No | G91.2 | N/A | Neurologic | Moderate | Mild reduction |
| 22 | 22 | Creutzfeldt-Jakob Disease, Sporadic | Dementia & Cognitive Disorders | Incidence 1-2 per million person-years globally; mean onset age 65-68 years (Lancet Infect Dis 2019) | Acquired / Multifactorial | PRNP (sporadic; not inherited) | 20p13 | Rapidly progressive dementia, myoclonus, ataxia, visual disturbances, akinetic mutism | 65+ years | MRI (cortical ribbon, basal ganglia DWI hyperintensity), EEG (PSWC), CSF RT-QuIC, 14-3-3, tau | No disease-modifying treatment; supportive care, symptomatic management, palliative care | No | A81.00 | 123400 | Neurologic | Severe | Reduced without treatment |
| 23 | 23 | Parkinson's Disease (Classical, Without Dyskinesia) | Neurologic Disorders | Approximately 1% of adults >60; ~1 million Americans (Parkinson's Foundation 2024) | Acquired / Multifactorial | LRRK2, SNCA, GBA (minority familial) | N/A | Bradykinesia, resting tremor, rigidity, postural instability; hyposmia, RBD, constipation (non-motor) | 65+ years | MDS-PD clinical diagnostic criteria, neurologic exam, DaTscan if uncertain, levodopa response trial | Levodopa/carbidopa, dopamine agonists, MAO-B inhibitors (rasagiline, selegiline), DBS for advanced disease, PT/OT | No | G20.A1 | 168600 | Neurologic | Moderate | Mild reduction |
| 24 | 24 | Essential Tremor | Neurologic Disorders | Approximately 4-5% of adults >=65; most common movement disorder in elderly (US Pharmacist; Tremor Journal) | Acquired / Multifactorial | N/A (some familial, unclear genes) | N/A | Bilateral action tremor of hands, head, voice; worsens with purposeful movement; may interfere with ADLs | 65+ years | MDS consensus criteria (action tremor >=3 years, bilateral upper limbs), exclude parkinsonism, TSH | Propranolol (first-line), primidone, topiramate, gabapentin; MR-guided focused ultrasound thalamotomy, DBS (refractory) | No | G25.0 | 190300 | Neurologic | Variable | None |
| 25 | 25 | Late-Onset Epilepsy | Neurologic Disorders | Annual incidence 85/100,000 at ages 65-69; 159/100,000 at >=80 years (Practical Neurology 2022) | Acquired / Multifactorial | N/A | N/A | New-onset seizures after age 60, typically focal impaired awareness; confusion, automatisms, postictal state | 65+ years | Detailed history, EEG, brain MRI to identify structural cause (stroke, tumor, neurodegeneration), metabolic panel | Levetiracetam (preferred in elderly), lamotrigine, lacosamide; avoid enzyme-inducing AEDs; treat underlying cause | No | G40.909 | N/A | Neurologic | Moderate | Mild reduction |
- Full dataset access
- Excel format
- Instant download